Platelet-rich Plasma With Topical Retinoids Versus Topical Retinoids Alone in Acne Vulgaris - Trial NCT06281782
Access comprehensive clinical trial information for NCT06281782 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Recruiting. The study focuses on Acne Vulgaris. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Jan 01, 2024
May 01, 2024
Primary Outcome
change of acne lasions
Summary
Acne vulgaris is the most common skin disease in adolescents and young adults. Adult or
 post-adolescent acne occurs in 12-14% of this population.It is a chronic, inflammatory
 disease of the pilosebaceous unit .The clinical features of acne include seborrhoea,
 non-inflammatory lesions (open and closed comedones), inflammatory lesions (papules and
 pustules), and various degrees of scarring.
 
 Platelet-rich plasma (PRP) is prepared by simple centrifugation of whole blood to concentrate
 platelets and simultaneously remove red blood cells. The resultant supernatant is the PRP
 that contains various growth factors, including platelet-derived growth factor (PDGF),
 transforming growth factor (TGF), fibroblast growth factor (FGF), vascular endothelial growth
 factor (VEGF), and hepatocyte growth factor (HGF).These growth factors are involved in the
 healing of soft tissue and can regulate cellular processes such as chemotaxis, angiogenesis,
 mitogenesis, differentiation, and metabolism .
 
 Topical retinoids are used in the treatment of both noninflammatory and inflammatory
 acne.Food and Drug Administration (FDA) approved three topical retinoids: adapalene,
 tazarotene, and tretinoin. These agents help normalize follicular keratinization and decrease
 keratinocyte cohesiveness, thereby reducing follicular occlusion and comedon formation
 .Topical retinoids also compete with factors involved in the acne inflammation response,
 enhance penetration of other topical acne medications, and accelerate the resolution of
 acne-induced post-inflammatory hyperpigmentation.
 
 Updates from the Global Alliance on Improving Outcomes in Acne consider topical retinoids as
 first-line therapy, individually or in combination with benzoyl peroxide. However, the common
 side effects of skin irritation and discomfort may impede adherence to long-term therapy.
 
 For patients with acne, combination therapy with a topical retinoid and platelet-rich plasma
 (PRP) has not yet been tested.
 
 PRP with topical retinoids will be evaluated and campared with topical retinoids alone in
 acne tretment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06281782
Non-Device Trial

